LaserStock29 wrote: skier59 wrote: I think we all know and feel that once we get the chance to treat NMIBC in the early stages, prior to patients going through all the other carp, our CR rates will jump up dramatically. It's sad that our SP gets knocked down on such low volume, but that's been going on for many many years. I think those days are soon coming to a close, and the next 6 months should be exciting for us ! Like all of you, I can hardly wait for us to start breaking into the $$$'s range.
Can we get the BTD and AA in one go or will these next 6 months turn into
Apply in 4Q 2022 for BTD then
Apply for AA in 1Q 2023
So by June 2023 we can just start to commercially get this going.
BTW Endocyte didnt' even get into Phase 3 before Novartis started negotiations.
Endocyte + Novartis Endocyte looked set to spend the next year or so working toward phase 3 data before Novartis stepped in. The use of small molecules could mean Novartis avoids the complications associated with antibody-based radiotherapeutics. This is embarassing .... our trial is Phase 2 Pivotal
No phase 3 required.
Negotiations should be starting within these 6 months as those 11 patients confirm safety for the 2nd dose.. and get a 90 day follow up..
There is absolutely zero arguement this board can give that some form of fda approval is necessary before a deal can be struck..
that is completely false...... Big pharma gets what they want..
AGM Roger is gonna have to lay this out ......... there isn't any more circus dancing, side stepping or finger pointing........ all the fingers are pointed at him this AGM.
Need to hear a real plan here.